Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Kennedy Capital Management LLC

Kennedy Capital Management LLC increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 281.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 111,098 shares of the biopharmaceutical company's stock after buying an additional 81,971 shares during the quarter. Kennedy Capital Management LLC owned about 0.19% of Agios Pharmaceuticals worth $3,651,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals during the 4th quarter worth $53,000. KBC Group NV lifted its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the period. AlphaQuest LLC boosted its holdings in shares of Agios Pharmaceuticals by 106.2% in the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $202,000.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Remove Ads

Agios Pharmaceuticals Stock Up 1.1 %

Shares of AGIO traded up $0.30 during mid-day trading on Tuesday, reaching $27.82. 607,625 shares of the company's stock were exchanged, compared to its average volume of 710,601. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 2.45 and a beta of 0.83. The company has a 50-day simple moving average of $31.12 and a two-hundred day simple moving average of $38.98.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Ratings Changes

AGIO has been the topic of a number of analyst reports. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.